ArticleThe Journal of clinical endocrinology and metabolism2025

The Risk of Adrenal Insufficiency After Treatment With Relatlimab in Combination With Nivolumab is Higher Than Expected.

Natalia Chamorro-Pareja et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.